Blood Cancer Journal - Table of Contents alert Volume 3 October 2013

Advertisement BD FACSCanto™ has 10-color capability.  Reliable performance, accuracy, and ease of use make the latest BD FACSCanto System a perfect 10 for today's busy clinical labs. Learn how you can achieve dependable outcomes while speeding workflow and reducing training requirements with clinical multi-color flow cytometry systems from BD Biosciences.  bdbiosciences.com/go/canto   TABLE OF CONTENTS Volume 3, October 2013 In this issue Original Articles Letter to the Editor Advertisement   The Emerging Role for PP2A in Hematologic Malignancies Topic Editor: Peter Ruvolo¦ Submission deadline: 30 Mar 2014 The aim of this Research Topic from Frontiers in Oncology is to review (a) PP2A isoforms and their targets that have been identified in leukemia, (b) the role of SET and CIP2A as inhibitors of PP2A, ( c) genetic suppression of PP2A by mutations, miRs, and epigenetic phenomenon, and (d) strategies to activate PP2A for therapy.  Find out more about how you can contribute to this RT    Sign up for e-alerts Web feed Advertisement Top cited articles from Blood Cancer Journal  Mutations and deletions of the SUZ12 polycomb gene in myeloproliferative neoplasms   DNMT3a mutations in high-risk myelodysplastic syndrome parallel those found in acute myeloid leukemia    Original Articles Top Role of microRNAs and microRNA machinery in the pathogenesis of diffuse large B-cell lymphoma S Caramuta, L Lee, D M Özata, P Akçakaya, P Georgii-Hemming, H Xie, R-M Amini, C H Lawrie, G Enblad, C Larsson, M Berglund and W-O Lui Blood Cancer J 2013 3: e152; 10.1038/bcj.2013.49 Abstract | Full Text The impact of TEL-AML1 (ETV6-RUNX1) expression in precursor B cells and implications for leukaemia using three different genome-wide screening methods Y Linka, S Ginzel, M Krüger, A Novosel, M Gombert, E Kremmer, J Harbott, R Thiele, A Borkhardt and P Landgraf Blood Cancer J 2013 3: e151; 10.1038/bcj.2013.48 Abstract | Full Text Phytohemagglutinin-induced IL2 mRNA in whole blood can predict bortezomib-induced peripheral neuropathy for multiple myeloma patients T Watanabe, M Mitsuhashi, M Sagawa, M Ri, K Suzuki, M Abe, K Ohmachi, Y Nakagawa, S Nakamura, M Chosa, S Iida and M Kizaki Blood Cancer J 2013 3: e150; 10.1038/bcj.2013.47 Abstract | Full Text Synergistic apoptotic response between valproic acid and fludarabine in chronic lymphocytic leukaemia (CLL) cells involves the lysosomal protease cathepsin B J-Y Yoon, D Szwajcer, G Ishdorj, P Benjaminson, W Xiao, R Kumar, J B Johnston and S B Gibson Blood Cancer J 2013 3: e153; 10.1038/bcj.2013.50 Abstract | Full Text Letter to the Editor Top Difficulties in immunofixation analysis: a concordance study on the IFM 2007-02 trial H Caillon, T Dejoie, A-G Le Loupp, C Azoulay-Fauconnier, D Masson, P Moreau, M Denis and H Avet-Loiseau Blood Cancer J 2013 3: e154; 10.1038/bcj.2013.51 Full Text You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2013 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.